Former Forest employees file US gender discrimination suit
This article was originally published in Scrip
Forest Laboratories is the latest pharma company to be embroiled in a case alleging sexual discrimination by former female sales reps. Sanford Wittels & Heisler, a prominent US law firm, has filed a suit on behalf of four former employees, and is seeking class-action status. The suit alleges the company systematically engaged in "company-wide" discriminatory treatment of female employees, particularly related to pregnancies, maternity leaves and responsibilities shouldered by women in the caring for young children.
You may also be interested in...
A handful of former female sales representatives suing Merck & Co. Inc. for gender discrimination, including an alleged bias against employees who took maternity leave, could become a very large group of women now that the lawsuit seeking $250m in damages has been granted conditional certification as a collective action under the Equal Pay Act (EPA).
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.